Talis Biomedical (NASDAQ:TLIS) Stock Price Down 1.7% – Should You Sell?

Talis Biomedical Co. (NASDAQ:TLIS) shares fell 1.7% during trading on Friday . The company traded as low as $1.72 and last traded at $1.72. 120 shares were traded during mid-day trading, a decline of 98% from the average session volume of 5,277 shares. The stock had previously closed at $1.75.

Talis Biomedical Stock Performance

The business has a 50 day simple moving average of $2.08 and a two-hundred day simple moving average of $6.06. The stock has a market cap of $3.13 million, a price-to-earnings ratio of -0.06 and a beta of 1.56.

Talis Biomedical (NASDAQ:TLIS) last issued its quarterly earnings results on Monday, August 19th. The company reported ($4.86) earnings per share (EPS) for the quarter. Talis Biomedical had a negative return on equity of 79.74% and a negative net margin of 5,784.73%.

Insider Transactions at Talis Biomedical

In other news, major shareholder Braden Michael Leonard purchased 13,167 shares of the firm’s stock in a transaction that occurred on Monday, August 26th. The stock was acquired at an average cost of $3.90 per share, for a total transaction of $51,351.30. Following the completion of the purchase, the insider now owns 216,736 shares of the company’s stock, valued at approximately $845,270.40. This trade represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last 90 days, insiders purchased 15,033 shares of company stock valued at $58,804. Insiders own 46.00% of the company’s stock.

About Talis Biomedical

Talis Biomedical Corporation operates as a molecular diagnostic company, focusing on developing medical devices for infectious diseases and other conditions at the point of care in the United States. Talis Biomedical Corporation was incorporated in 2013 and is headquartered in Chicago, Illinois.